{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infusion+of+albumin%2Fsaline&page=2",
    "query": {
      "intervention": "Infusion of albumin/saline",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 29,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infusion+of+albumin%2Fsaline&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infusion+of+albumin%2Fsaline&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T20:33:56.003Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06812390",
      "title": "Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cirrhosis",
        "Ascites Hepatic"
      ],
      "interventions": [
        {
          "name": "Albumin infusion (25% albumin)",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline (0.9% NaCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anahita Rabiee MD MHS",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-02-28",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2025-03-11",
      "last_synced_at": "2026-10-06T20:33:56.003Z",
      "location_count": 1,
      "location_summary": "West Haven, Connecticut",
      "locations": [
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06812390"
    },
    {
      "nct_id": "NCT00199862",
      "title": "Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Colorectal Neoplasms",
        "Colorectal Cancer",
        "Colorectal Tumor",
        "COlorectal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Iodine-124 labeled humanized A33 (antibody)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2004-02",
      "completion_date": "2025-07-02",
      "has_results": false,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-10-06T20:33:56.003Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00199862"
    },
    {
      "nct_id": "NCT02922413",
      "title": "Panhematin for Prevention of Acute Attacks of Porphyria",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Intermittent Porphyria",
        "Hereditary Coproporphyria",
        "Variegate Porphyria"
      ],
      "interventions": [
        {
          "name": "Hemin for injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2015-10-30",
      "completion_date": "2023-12-27",
      "has_results": true,
      "last_update_posted_date": "2026-01-30",
      "last_synced_at": "2026-10-06T20:33:56.003Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02922413"
    },
    {
      "nct_id": "NCT00798915",
      "title": "Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Glucose-dependent Insulinotropic Polypeptide (GIP)",
          "type": "DRUG"
        },
        {
          "name": "Xenin-25",
          "type": "DRUG"
        },
        {
          "name": "Glucose-dependent Insulinotropic Polypeptide plus Xenin-25",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2008-12",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2018-05-03",
      "last_synced_at": "2026-10-06T20:33:56.003Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00798915"
    },
    {
      "nct_id": "NCT03410030",
      "title": "Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Pancreas Cancer",
        "Pancreatic Adenocarcinoma Resectable",
        "Pancreatic Ductal Adenocarcinoma",
        "Pancreas Metastases"
      ],
      "interventions": [
        {
          "name": "High Dose Ascorbic Acid 25 g/m^2",
          "type": "DRUG"
        },
        {
          "name": "Nanoparticle Paclitaxel protein bound 125mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin 25mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine 1000mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "High Dose Ascorbic Acid 37.5 g/m^2",
          "type": "DRUG"
        },
        {
          "name": "High Dose Ascorbic Acid 56.25 g/m^2",
          "type": "DRUG"
        },
        {
          "name": "High Dose Ascorbic Acid 75 g/m^2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HonorHealth Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2017-12-15",
      "completion_date": "2023-09-06",
      "has_results": true,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-10-06T20:33:56.003Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03410030"
    },
    {
      "nct_id": "NCT01951716",
      "title": "Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Does the Vagus Nerve Mediate the Effects of Xenin-25"
      ],
      "interventions": [
        {
          "name": "Graded Glucose Infusion with Placebo",
          "type": "DRUG"
        },
        {
          "name": "Graded Glucose Infusion with GIP Alone",
          "type": "DRUG"
        },
        {
          "name": "Graded Glucose Infusion with xenin-25 alone",
          "type": "DRUG"
        },
        {
          "name": "Graded Glucose Infusion with GIP plus xenin-25",
          "type": "DRUG"
        },
        {
          "name": "Meal Tolerance Test with Placebo",
          "type": "DRUG"
        },
        {
          "name": "Meal Tolerance Test with xenin-25",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-01",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2018-04-26",
      "last_synced_at": "2026-10-06T20:33:56.003Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01951716"
    },
    {
      "nct_id": "NCT00617864",
      "title": "The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ovarian Hyperstimulation Syndrome"
      ],
      "interventions": [
        {
          "name": "Human Albumin Infusion",
          "type": "DRUG"
        },
        {
          "name": "Saline Infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "42 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 42 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2007-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-02-22",
      "last_synced_at": "2026-10-06T20:33:56.003Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00617864"
    },
    {
      "nct_id": "NCT00220740",
      "title": "Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating"
      ],
      "interventions": [
        {
          "name": "Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified",
          "type": "DRUG"
        },
        {
          "name": "Albumin (Human) 25%, United States Pharmacopeia (USP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 117,
      "start_date": "2004-04",
      "completion_date": "2006-06",
      "has_results": true,
      "last_update_posted_date": "2016-03-23",
      "last_synced_at": "2026-10-06T20:33:56.003Z",
      "location_count": 6,
      "location_summary": "New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00220740"
    },
    {
      "nct_id": "NCT03585257",
      "title": "HEAL STUDY (Hepatic Encephalopathy and Albumin Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cirrhosis",
        "Hepatic Encephalopathy",
        "Minimal Hepatic Encephalopathy",
        "Covert Hepatic Encephalopathy"
      ],
      "interventions": [
        {
          "name": "25% IV albumin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Hunter Holmes Mcguire Veteran Affairs Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2018-06-20",
      "completion_date": "2022-03-30",
      "has_results": false,
      "last_update_posted_date": "2022-05-31",
      "last_synced_at": "2026-10-06T20:33:56.003Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03585257"
    },
    {
      "nct_id": "NCT04895358",
      "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "liposomal doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "normal saline",
          "type": "DRUG"
        },
        {
          "name": "dextrose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 342,
      "start_date": "2021-06-18",
      "completion_date": "2027-12-18",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-06T20:33:56.003Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04895358"
    }
  ]
}